Researchers at The University of Texas MD Anderson Cancer Center have found that renal medullary carcinoma (RMC) cells use an adaptive mechanism called “myeloid mimicry” to hide from the immune system and promote disease hyperprogression after immunotherapy, highlighting specific targets that overcome treatment resistance in preclinical models.
Continue Reading this article here
